Artemis Bow Investment Fund II LLC has filed a new offering to raise up to $10 million under Rule 506(b) of the Securities Act. This filing is significant as it reflects the company's strategy to attract private investments, which can provide the necessary capital for growth and expansion.
Background
Artemis Bow Investment Fund II LLC is a limited liability company incorporated in Delaware. The company is based in Tampa, Florida, and was formed in 2026. The filing on October 29, 2026, is categorized under the SEC Form D, which is typically used for private placements.
What the Filing Says
The filing indicates that the offering is not an amendment and that the date of the first sale is yet to occur. The total offering amount is set at $10 million, with no amounts sold yet. The company has also noted a minimum investment acceptance of $50,000.
Impact
This offering may affect various stakeholders, including potential investors who are interested in equity-type securities. The filing indicates that there are provisions for non-accredited investors, which could broaden the pool of potential participants in this investment opportunity.
What's Next
The filing does not say what happens next.
Company Details
Artemis Bow Investment Fund II LLC is classified as a limited liability company and was formed in 2026. The company is incorporated in Delaware but operates out of Tampa, Florida. Its business address is 1401 E. 22ND AVE., Tampa, FL 33605, and the business phone number is 646-701-4536.
Management
The filing identifies Camille Renshaw as an Executive Officer of the company, who is also based at the same address in Tampa, Florida. This indicates a centralized management structure that may facilitate decision-making processes related to the investment fund.
Offering Specifics
The offering is categorized under the Commercial industry group and is structured as an equity-type security. Notably, the filing states that the offering is not a business combination transaction, which suggests that the fund is focused on direct investments rather than mergers or acquisitions.
Investor Information
The offering allows for non-accredited investors to participate, which could potentially increase the number of investors interested in the fund. However, as of the filing date, there have been no investments made, and the total amount remaining for sale is still $10 million.
Use of Proceeds
The filing does not specify how the proceeds from the offering will be utilized, leaving potential investors without detailed insights into the fund's planned investments or operational strategies.
Read Next
Mirum Pharmaceuticals reports stock sale by former officer
Basswood Financial Fund sells shares of Regional Management Corp.
Basswood Financial Fund Files to Sell Shares in Regional Management
HCA Healthcare Officer Jon M. Foster Files to Sell Shares
Regional Management Corp. Sees Shareholder Stock Sale
Wampler Kira Scherer Reports Stock Transactions for Doximity










